The Exchange has sought clarification from Claris Lifesciences Ltd as under: "This is with reference to the Board meeting outcome on October 12, 2017, which inter-alia states "The Board took note of the net cash consideration received by the Company from the sale of the Company's Specialty Injectable Business to the Baxter Group, post repayment of debt net of cash, working capital adjustments and escrow/ hold back adjustments."...